FDA GLP-1 Eye Warning: New NAION Label for All GLP-1s
On November 9, 2026, the FDA said every GLP-1 medicine, including Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo, must add a warning about NAION, a rare problem where blood flow to the optic nerve drops and vision in one eye can be lost. In pooled trials it happened about 6.4 times per 100,000 person-years on GLP-1s versus 3.8 on placebo or other diabetes drugs, so it stays rare. The FDA's advice is simple: call your doctor right away about sudden vision loss in one eye, and do not stop your medicine on your own. Your daily plan does not change, and Sharpy keeps your protein and 20-minute workouts on track.
What is the new FDA warning on GLP-1 drugs? On November 9, 2026, the FDA said all GLP-1 medicines must add a warning about NAION, a rare eye condition that can cause sudden vision loss in one eye. The warning goes in the Warnings and Precautions section of each label. It covers Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Foundayo, Trulicity, Victoza, Saxenda and the rest of the class. The risk is small, and the FDA did not tell anyone to stop their medicine.
This is a change for the US. Until today, the US labels did not list NAION, while Europe has listed it as a very rare semaglutide side effect since 2025. We covered the earlier studies in Ozempic vision loss (NAION). This guide is about the new FDA action and what it means for you.
What is NAION, in plain words?
NAION stands for non-arteritic anterior ischemic optic neuropathy. Think of it as a small stroke of the optic nerve, the cable that carries what your eye sees to your brain. Blood flow to the front of that nerve drops, and part of the nerve is hurt.
It is uncommon in everyone, not only in people on GLP-1s. The FDA puts it at 2.3 to 10.2 cases per 100,000 adults over 50 each year.
Which drugs get the new NAION warning?
The FDA is requiring the makers of all GLP-1 receptor agonists to update their labels. Here is the list the FDA gave.
| Drug (generic) | Main use | Year approved |
|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes | 2017 |
| Rybelsus (semaglutide pill) | Type 2 diabetes | 2019 |
| Wegovy (semaglutide) | Weight management | 2021 |
| Mounjaro (tirzepatide) | Type 2 diabetes | 2022 |
| Zepbound (tirzepatide) | Weight management | 2023 |
| Foundayo (orforglipron pill) | Weight management | 2026 |
| Trulicity (dulaglutide) | Type 2 diabetes | 2014 |
| Victoza and Saxenda (liraglutide) | Diabetes / weight | 2010 / 2014 |
| Xultophy, Soliqua (combos with insulin) | Type 2 diabetes | 2016 |
| Exenatide (generic of Byetta) | Type 2 diabetes | 2005 |
That means NAION and Zepbound, NAION and Mounjaro, and NAION and Foundayo are now part of the same story. Earlier worry focused on semaglutide. The FDA said NAION cases have been reported for every GLP-1 product on the market.
How rare is NAION on GLP-1 drugs?
The FDA looked at three kinds of data. Here are the numbers it shared.
| Data the FDA reviewed | What it found |
|---|---|
| 126 randomized trials, 134,253 people | 10 probable NAION cases on GLP-1s, 5 on placebo, 0 on other diabetes drugs |
| Same trials, as a rate | 6.4 per 100,000 person-years on GLP-1s vs 3.8 on comparators |
| Sentinel study, adults with type 2 diabetes starting a drug 2019 to 2024 | 26 to 32 cases per 100,000 person-years across groups |
| GLP-1 vs SGLT-2 drugs (like Jardiance) | Hazard ratio 1.19, not statistically clear |
| GLP-1 vs DPP-4 drugs (like Januvia) | Hazard ratio 1.43, a small but real increase |
| Animal studies | No mechanism found |
In plain words: the extra risk, if real, is a few cases per 100,000 people per year. The FDA said its review of reports sent in by doctors and patients was hard to read, because the things that raise NAION risk are common in people who take GLP-1s anyway. Even so, the agency decided the signal was strong enough for a label warning.
Why is the FDA acting now?
The trigger was a July 2024 study in JAMA Ophthalmology from Massachusetts Eye and Ear, which linked semaglutide to more NAION. The FDA said that study had several limits but needed a closer look. Since then, Europe's drug agency listed NAION as a very rare semaglutide side effect (up to 1 in 10,000 people), and the UK and Australia added warnings too. The FDA's own review is what led to today's class-wide change.
NAION symptoms: what to watch for
The FDA lists these signs:
- Sudden, painless vision loss in one eye, often noticed on waking.
- Blurry or missing parts of what you see.
- Colors that look washed out or wrong.
- Central vision that is less sharp.
If any of these happen, contact a health care professional right away. Same-day eye care matters. Doctors are told to send people with suspected NAION to an eye specialist (ophthalmologist) promptly.
Who has a higher NAION risk?
The FDA names these risk factors: smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. Many of these overlap with the reasons people take a GLP-1. If NAION has already happened in one eye, the risk in the other eye is higher.
If you have had NAION before, tell your prescriber before you start or keep taking a GLP-1. The FDA tells doctors that past NAION raises the risk of it coming back.
Should you stop your GLP-1?
No, not on your own. The FDA did not tell people without symptoms to stop. If NAION does happen, the FDA says to talk with your health care professional about whether to continue or stop. Doctors are told to consider stopping the GLP-1 in that case unless the benefits clearly outweigh the risk.
Stopping suddenly has its own costs, like weight regain and higher blood sugar. Read how to stop a GLP-1 without rebound if you and your doctor decide to stop.
What changes in your daily routine?
Nothing new, except knowing the eye symptoms. Keep doing the things that make GLP-1 weight loss healthier. Several NAION risk factors, like high blood pressure and sleep apnea, tend to improve as weight comes down. Losing fat while keeping muscle is the goal. Sharpy gives you one daily protein target, one 20-minute workout and one Shape Score, so you can see that the weight you lose is mostly fat. For the protein side, see your protein target on GLP-1.
When will the new labels show up?
The FDA is requiring each company to add the warning. Updated labels will appear on DailyMed as each one is revised. Eli Lilly and Novo Nordisk did not comment right away, per Reuters. For the full list of other long-term risks already on the labels, see GLP-1 long term side effects. If you take tirzepatide, our Zepbound vision loss guide covers what the Zepbound and Mounjaro studies show. For the court cases over vision loss and stomach injuries, see our Ozempic lawsuit update.
Bottom line
The FDA now treats NAION as a class-wide GLP-1 risk. It is rare, it can be serious, and the warning sign is sudden vision loss in one eye. Know the symptoms, get same-day care if they appear, and keep your medicine decisions with your prescriber. Then keep building strength and protein habits with Sharpy.
Sources
- FDA Drug Safety Communication: FDA requires safety labeling changes for GLP-1 RAs due to potential increased risk of rare but serious eye condition, November 9, 2026
- Reuters via Yahoo News: US FDA orders new eye risk warnings for Ozempic, Zepbound, November 9, 2026
- EMA: PRAC concludes eye condition NAION is a very rare side effect of semaglutide, June 2025
- MHRA Drug Safety Update: semaglutide and risk of NAION
Questions people ask
What did the FDA announce about GLP-1 drugs and eyes?
In a Drug Safety Communication dated November 9, 2026, the FDA said it is requiring the makers of all GLP-1 receptor agonist medicines to add information about the potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy) to the Warnings and Precautions section of their labels.
Is the new GLP-1 eye warning a boxed warning?
No. The FDA is adding NAION to the Warnings and Precautions section, not a boxed warning. Many GLP-1 labels, such as Ozempic, Wegovy, Mounjaro and Zepbound, already carry a separate boxed warning about thyroid C-cell tumors.
Does the NAION warning apply to Zepbound and Mounjaro?
Yes. The FDA requirement covers all GLP-1 receptor agonists, and its list includes tirzepatide (Mounjaro, Zepbound) as well as semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide combinations and orforglipron (Foundayo). The FDA said NAION cases have been reported for all currently marketed GLP-1 products.
How rare is NAION on GLP-1 drugs?
Rare. In an FDA meta-analysis of 126 trials with about 134,000 people, there were 6.4 probable NAION cases per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. That was 10 cases on GLP-1s and 5 on placebo in total.
What are the symptoms of NAION?
Per the FDA: sudden, painless vision loss in one eye that you may notice when you wake up, blurred or missing parts of your vision, colors that look off, or less sharp central vision. Contact a health care professional right away if this happens.
Is NAION permanent?
It can be. The FDA says NAION may lead to permanent loss of sight in some cases. If it happens in one eye, the risk of it happening in the other eye goes up. That is why sudden vision changes need same-day care.
Should I stop my GLP-1 because of the eye warning?
Do not stop on your own. The FDA tells patients to talk with their health care professional about whether to continue if NAION happens. For people without symptoms, the FDA did not tell anyone to stop. Ask your prescriber if you have a history of NAION or several risk factors.